ORAMED PHARMACEUTICALS INC.
ORMPOramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Drugs in Pipeline
9
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
10dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ORMP Earnings Report
EPS Est: $0.43 | FQ end 2026-06
How ORMP's past catalysts played out
ORMD-0801 QD
Nonalcoholic Steatohepatitis (NASH)
ORMD-0801 (qd)
Type 2 Diabetes Mellitus
ORMD-0801 Dose # 1
Diabetes Mellitus Type 2
ORMD-0801
Diabetes Type 2
ORMD-0801 Capsules
Diabetes Mellitus Type 1
ORMD-0801 Treatment A
Type 1 Diabetes
ORMD-0801 (Insulin) capsule 8 mg BD
Diabetes Mellitus, Type 2
Oral Insulin
Non-Alcoholic Steatohepatitis (NASH)
Cohort A: ORMD-0801
T2DM (Type 2 Diabetes Mellitus)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ORMD-0801 QD | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
ORMD-0801 (qd) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ORMD-0801 Dose # 1 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
ORMD-0801 | Phase 2 | Diabetes Type 2 | - | - |
ORMD-0801 Capsules | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ORMD-0801 Treatment A | Phase 2 | Type 1 Diabetes | - | - |
ORMD-0801 (Insulin) capsule 8 mg BD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Oral Insulin | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Cohort A: ORMD-0801 | Phase 2 | T2DM (Type 2 Diabetes Mellitus) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ORAMED PHARMACEUTICALS INC.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in ORAMED PHARMACEUTICALS INC.'s (ORMP) pipeline across Phase 2. Its lead program is ORMD-0801 QD (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ORAMED PHARMACEUTICALS INC.'s next FDA catalyst?→
ORAMED PHARMACEUTICALS INC.'s (ORMP) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORMP biotech catalysts?→
Add ORMP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ORAMED PHARMACEUTICALS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.